MannKind (MNKD) Shows Promising Results in AFREZZA Study in Combo with Basal Insulin
Tweet Send to a Friend
MannKind Corporation (Nasdaq: MNKD) today announced that results of a new 16-week trial show that the investigational ultra rapid acting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
